ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Credit Rating
Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating by India Ratings and Research Private Limited for Non-Convertible Debentures (NCDs) programme of Rs.50 Crore of Astec LifeSciences Limited. ASTEC LIFESCIENCES LIMITED - 533138 - Reply On Significant Increase In The Volume Of Security Across Exchanges, In The Recent Past
With reference to your Notice Ref. No.: L/SURV/ONL/PV/MG/ 2023-2024 / 126 dated 8th June, 2023, we wish to inform you that as a Listed Company, we are conscious of our responsibility to disseminate to the Stock Exchanges, information that could have an impact on the price of the Company's shares. Consistent with this approach, we have been promptly disseminating to the Stock Exchanges, events or information which are required to be disclosed pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Listing Regulations'). We hereby confirm that we are in compliance with respect to disclosures that are required to be made under the Listing Regulations and also confirm that there are no developments that have taken place requiring mandatory disclosure under Listing Regulations or the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ('PIT Regulations'). ASTEC LIFESCIENCES LIMITED - 533138 - Clarification sought from Astec Lifesciences Ltd
The Exchange has sought clarification from Astec Lifesciences Ltd on June 8, 2023, with reference to Movement in Volume.The reply is awaited. ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
This is to inform you under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') that Astec LifeSciences Limited will be participating an event 'Trinity India - 2023' (Annual Investor Conference) organized by Battlival & Karani Securities India Private Limited, scheduled to be held today, i.e., on Thursday, 1st June, 2023 at Mumbai. ASTEC LIFESCIENCES LIMITED - 533138 - Compliances-Reg.24(A)-Annual Secretarial Compliance
In compliance with Regulation 24A(2) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, the Annual Secretarial Compliance Report of Astec LifeSciences Limited ('the Company') for the Financial Year ended 31st March, 2023, issued by M/s. BNP & Associates, Company Secretaries. ASTEC LIFESCIENCES LIMITED - 533138 - Revised Disclosure Of Related Party Transactions For The Half Year Ended March 31, 2023
Please find enclosed herewith, the revised disclosure of Related Party Transactions for the Half Year ended 31st March, 2023, pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the format specified under SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22nd November, 2021. The above information is also being uploaded on the Company's website, viz., www.astecls.com. ASTEC LIFESCIENCES LIMITED - 533138 - Intimation Of Grant Of Options Under Astec Lifesciences Limited - Employees Stock Option Plan, 2012
Please find attached Intimation of Grant of Options under Astec LifeSciences Limited - Employees Stock Option Plan, 2012
Astec LifeSciences reports net loss of 5 Cr down by 111.6% YoY in Q4, Board declares dividend
During today's closing session, Astec Lifesciences, a small cap company, recorded a market cap of 2,658.92 Cr. ASTEC LIFESCIENCES LIMITED - 533138 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 read with Schedule III and Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed, copies of the newspaper publication of the Audited Financial Results for the Quarter and Financial Year ended 31st March, 2023 (approved by the Board of Directors at its Meeting held on Tuesday, 2nd May, 2023, upon recommendation of the Audit Committee), published by the Company today, i.e., on Wednesday, 3rd May, 2023 in Business Standard (in English language) and Mumbai Lakshdeep (in Marathi language). Q4FY23 Quarterly & FY23 Annual Result Announced for Astec Lifesciences Ltd.
Agrochemicals company Astec Lifesciences announced Q4FY23 & FY23 results: Q4FY23: The company reported a consolidated total income of Rs 129.5 crore in Q4FY23 as compared to Rs 278.8 crore in Q4FY22 Company reported consolidated EBITDA of Rs 8.0 crore in Q4FY23 as compared to Rs 72.3 crore in Q4FY22 Gross margin stood at 32.1% in Q4FY23 as compared to 39.6% in Q4FY22 EBITDA margin was at 6.2% in Q4FY23 as compared to 25.9% in Q4FY22 FY23: Consolidated total income of Rs 641.2 crore in FY23 as compared to Rs 687.0 crore in FY22, a decline of 6.7% YoY Company reported consolidated EBITDA of Rs 89.3 crore in FY23 as compared to Rs 164.5 crore in FY22 Company reported Profit after tax of Rs 25.6 crore in FY23 as compared to Rs 89.8 crore in FY22 Gross margin was lower at 36.1% in FY23 as compared to 42.8% in FY22 EBITDA margin declined to 13.9% in FY23 from 23.9% in FY22 Commenting on the performance, N B Godrej, Chairman, Astec LifeSciences, said: "High level of channel inventories in India as well as key export markets, resultant demand-supply imbalance and subsequent correction in prices of key Active Ingredients (AI) continued to pose challenges for Indian Agrochemical sector, primarily in the second half of the year. Astec also witnessed unprecedented drop in volumes as well as realisations in H2FY23 and as a result, the company reported decline in topline and profitability in FY23 as compared to the previous year. Contract manufacturing (CMO) segment performance was in line with our expectations and robust topline growth in CMO was also accompanied by improved profitability. Enterprise business revenues and margins were lower than the previous year on account of volume and pricing headwinds. In April’23, Astec inaugurated a new state-of-the-art Research & Development centre, named “Adi Godrej Centre for Chemical Research and Development” in Rabale, Maharashtra. Despite challenges in the short run, Astec continued to maintain a steadfast focus on long-term growth and value creation which is reflected from the substantial investment in a future-ready R&D; facility. The facility, equipped with synthesis lab, formulation lab as well as sophisticated safety infrastructure will further augment Astec’s R&D; capabilities and enable accelerated growth of CMO business." Result PDF